A second pre-planned interim overall survival (OS) analysis of a Phase 3 clinical trial, SOPHIA, evaluating MacroGenics’ (NASDAQ:MGNX)
margetuximab, an HER2-targeting monoclonal antibody, plus chemo
compared to Roche’s Herceptin (trastuzumab) plus chemo in patients with
HER2-positive metastatic breast cancer showed a median increase of 1.8
months (21.6 months vs. 19.8 months).
The final pre-specified OS analysis should happen in 2020 after 385 events (deaths) have occurred.
On the safety front, the rate of
serious/life-threatening treatment-related adverse events was 55% in the
margetuximab arm compared to 53% in the trastuzumab arm.
Detailed results from the second OS analysis will be presented at the San Antonio Breast Cancer Symposium in December.
https://seekingalpha.com/news/3508121-macrogenics-margetuximab-shows-survival-benefit-late-stage-breast-cancer-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.